Table 1 Baseline characteristics of enrolled patients with catheter ablation
From: Laryngeal mask versus facemask in the respiratory management during catheter ablation
Variable | Facemask group (n = 10) | Laryngeal mask group (n = 14) | p value |
|---|---|---|---|
Age, years | 67.9 ± 9.8 | 66.7 ± 9.6 | 0.771 |
Male sex, n (%) | 6 (60) | 10 (71.4) | 0.559 |
BMI, kg/m2 | 23.1 ± 2.4 | 24.0 ± 3.1 | 0.425 |
Hypertension, n (%) | 4 (40) | 7 (50) | 0.697 |
Diabetes mellitus, n (%) | 1 (10) | 3 (21.4) | 0.615 |
Dyslipidemia, n (%) | 1 (10) | 2 (14.3) | 0.759 |
Echocardiography data | |||
LA diameter (mm) | 40.2 ± 6.3 | 36.1 ± 6.2 | 0.131 |
Ejection fraction (%) | 67.9 ± 12.3 | 68.0 ± 7.3 | 0.981 |
Laboratory data | |||
eGFR (ml/min/kg) | 58.9 ± 13.2 | 58.8 ± 10.9 | 0.989 |
Ln BNP (pg/ml) | 4.3 ± 1.2 | 4.1 ± 0.6 | 0.560 |
Ln C-reactive protein (mg/ml) | −2.7 ± 0.8 | −2.3 ± 1.2 | 0.324 |
Hemoglobin (g/dl) | 14.2 ± 1.1 | 14.2 ± 1.9 | 0.977 |
Types of atrial fibrillation | |||
Paroxysmal atrial fibrillation | 6 (60) | 8 (57.1) | 0.889 |
Persistent atrial fibrillation | 4 (40) | 6 (42.9) | 0.895 |
3% ODI (n/h) | 18.1 ± 12.1 | 17.7 ± 14.7 | 0.958 |
Analyzed ETCO2 samples (points/a patient) | 1722.3 ± 682.0 | 1435.9 ± 662.7 | 0.314 |
Dose of Dexmedetomidine Hydrochloride (μg/kg) | 2.7 ± 0.5 | 2.3 ± 0.6 | 0.103 |
Dose of Propofol (mg/kg) | 1.6 ± 0.6 | 1.9 ± 0.7 | 0.244 |